Know Cancer

forgot password

A Randomized Phase 2 Trial Comparing Amrubicin Versus Topotecan as Second-Line Treatment in Patients With Extensive Small Cell Lung Cancer Sensitive to First-Line Chemotherapy

Phase 2
18 Years
Not Enrolling
Small Cell Lung Cancer

Thank you

Trial Information

A Randomized Phase 2 Trial Comparing Amrubicin Versus Topotecan as Second-Line Treatment in Patients With Extensive Small Cell Lung Cancer Sensitive to First-Line Chemotherapy

Inclusion Criteria:

- Histological or cytological diagnosis of SCLC

- Extensive disease (ED) at time of study entry

- Response to first-line platinum-based chemotherapy

- Recurrent or progressive SCLC ≥90 days after completion of first-line therapy

- At least 18 years of age

- ECOG Performance Status of 0, 1, or 2

- Measurable disease defined by RECIST criteria

- Measurable disease: The presence of at least one measurable lesion. If only one
lesion is present, the neoplastic nature of the disease site should be confirmed
by histology and/or cytology.

- Measurable lesion: Lesions that can be accurately measured in at least one
dimension with the longest diameter ≥20mm using conventional techniques or ≥10mm
using spiral CT scans.

CT (including spiral CT) scans and MRI are the preferred methods of measurement; however,
chest x-rays are acceptable if the leions are clearly defined and surrounded by aerated
lung. Clinically detected lesions will only be considered measurable when they are
superficial (eg., skin nodules and palpable lymph nodes). For the case of skin lesions,
documentation by color photography, including a ruler to estimate the size of the lesion
is required.

- Adequate organ function including the following:

- Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count
(ANC) ≥1500 cells/μL, platelet count ≥100,000 cells/μL and hemoglobin ≥9 g/dL

- Hepatic: bilirubin ≤1.5 X ULN; alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) ≤3.0 X ULN

- Renal: serum creatinine <2.0mg/dL or calculated creatinine clearance >60mL/min

- Cardiac: Left ventricular ejection fraction (LVEF) ≥50%

- Negative serum pregnancy test at the time of enrollment for women of child-bearing
potential. For men and women of child-producing potential, use of effective
contraceptive methods during the study.

- Ability to understand the requirements of the study, provide written informed consent
and authorization of use and disclosure of protected health information, and agree to
abide by the study restrictions and to return for the required assessments

Exclusion Criteria:

- Pregnant or nursing women

- Chest radiotherapy within the previous 28 days or other radiotherapy within the
previous 14 days. Recovery from the acute toxic effects of radiation required prior
to study enrollment. Measurable lesions that have been previously irradiated must be
enlarging to be considered target lesions. Prior radiation therapy allowed to <25% of
the bone marrow.

- More than 1 prior chemotherapy regimen for SCLC

- Prior anthracycline treatment

- Participation in any investigational drug study within 28 days prior to study entry

- Patients with second primary malignancy (except in situ carcinoma of the cervix or
adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated
at least 5 years previously with no evidence of recurrence; prior low grade [Gleason
score ≤6] localized prostate cancer is allowed)

- Concurrent severe or uncontrolled medical disease (i.e., active systemic infection,
diabetes, hypertension, coronary artery disease, congestive heart failure) that, in
the opinion of the Investigator, would compromise the safety of the patient or
compromise the ability of the patient to complete the study.

- Symptomatic central nervous system metastases. Patients with asymptomatic brain
metastases are allowed. The patient must be stable after radiotherapy for ≥2 weeks
and off corticosteroids for ≥1 week.

- History of interstitial lung disease or pulmonary fibrosis

Type of Study:


Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective tumor response rate

Outcome Time Frame:

Until Disease Progression

Safety Issue:


Principal Investigator

Richard S Ungerleider, MD

Investigator Role:

Study Director

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

April 2006

Completion Date:

January 2009

Related Keywords:

  • Small Cell Lung Cancer
  • small cell lung cancer
  • amrubicin
  • Lung Neoplasms
  • Small Cell Lung Carcinoma



Sinai Hospital of Baltimore Baltimore, Maryland  21225
Virginia Oncology Associates Newport News, Virginia  23606
Comprehensive Cancer Centers of Nevada Las Vegas, Nevada  89109
Ocala Oncology Center Ocala, Florida  34474
Cancer Centers of the Carolinas Greenville, South Carolina  29605
Moores UCSD Cancer Center La Jolla, California  92093-0658
Missouri Cancer Associates Columbia, Missouri  65201
John B. Amos Cancer Center Columbus, Georgia  31904
Tyler Cancer Center Tyler, Texas  75702
Hope Center Terre Haute, Indiana  47809
Willamette Valley Cancer Center Eugene, Oregon  97401-8122
St. Joseph Oncology, Inc. Saint Joseph, Missouri  64506
Texas Oncology, PA Dallas, Texas  75246-2006
Medical Oncology Associates Kingston, Pennsylvania  18704
Central Indiana Cancer Centers Indianapolis, Indiana  46227
Texas Cancer Center at Medical City Dallas, Texas  75230
West Texas Cancer Center Odessa, Texas  79761
Hematology Oncology Associates Phoenix, Arizona  85012
Texas Oncology Cancer Center Austin, Texas  78731
Northwestern Carolina Oncology & Hematology Hickory, North Carolina  28601
Minnesota Oncology Hematology, PA Minneapolis, Minnesota  55404
New York Oncology Hematology, PC Albany, New York  12208
Puget Sound Cancer Center Edmonds, Washington  98026
Maryland Oncology Hematology, PA Columbia, Maryland  21044
Cancer Centers of Florida, PA Orlando, Florida  32822
Northwest Cancer Specialists Portland, Oregon  97225
Alison Cancer Center Midland, Texas  79701
Northwest Cancer Specialists - Vancouver Cancer Center Vancouver, Washington  98684
Birmingham Hematology & Oncology Birmingham, Alabama  35205
Alta Bates Medical Center - Comprehensive Cancer Center Berkeley, California  94704
Rocky Mountain Cancer Center - Denver Denver, Colorado  80218
Rocky Mountain Cancer Center - Sky Ridge Lone Tree, Colorado  80124
Cancer Care & Hematology Specialists of Chicago Niles, Illinois  60714
Oncology & Hematology of Central Illinois Peoria, Illinois  61602
Blessing Cancer Center Quincy, Illinois  62301
Norton Healthcare - Louisville Oncology Louisville, Kentucky  40202
Johns Hopkins Hospital - The Bunting Blaustein Cancer Research Building Baltimore, Maryland  21231
Alliance Hematology Oncology, PA - Carroll County Cancer Center Westminster, Maryland  21157
Arch Medical Services - Center for Cancer Care & Research St Louis, Missouri  63141
Hematology/Oncology Consultants St. Louis, Missouri  63136
SUNY Upstate Medical University - Regional Oncology Center Syracuse, New York  13210
Cancer Centers of North Carolina Raleigh, North Carolina  27607
Texas Oncology - Sammons Cancer Center Dallas, Texas  75246
Texas Oncology Cancer Care & Research Center Waco, Texas  76712
Texas Oncology, PA - Deke Slayton Cancer Center Webster, Texas  77598
Oncology & Hematology Associates of SW Virginia, Inc. Salem, Virginia  24153